Role of metabolism in drug-induced idiosyncratic hepatotoxicity.
about
Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuriesTyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?A New Structure-Activity Relationship (SAR) Model for Predicting Drug-Induced Liver Injury, Based on Statistical and Expert-Based Structural AlertsPatient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicityAnalytical tools and approaches for metabolite identification in early drug discovery.Post-acquisition analysis of untargeted accurate mass quadrupole time-of-flight MS(E) data for multiple collision-induced neutral losses and fragment ions of glutathione conjugates.Two-photon fluorescent probe for revealing drug-induced hepatotoxicity via mapping fluctuation of peroxynitriteLong-term culture of human liver tissue with advanced hepatic functions.Prediction models for drug-induced hepatotoxicity by using weighted molecular fingerprints.Mechanisms of drug-induced liver injury: from bedside to bench.Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicitySafety and tolerability of antiepileptic drug treatment in children with epilepsy.Quinone Methide Bioactivation Pathway: Contribution to Toxicity and/or Cytoprotection?Screening and characterization of reactive compounds with in vitro peptide-trapping and liquid chromatography/high-resolution accurate mass spectrometry.Chiral toxicology: it's the same thing...only different.Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury.A malleable catalyst dominates the metabolism of drugs.Detection of reactive metabolites using isotope-labeled glutathione trapping and simultaneous neutral loss and precursor ion scanning with ultra-high-pressure liquid chromatography triple quadruple mass spectrometryGenetic Variations in TXNRD1 as Potential Predictors of Drug-Induced Liver Injury.Identification of protein targets of reactive metabolites of tienilic acid in human hepatocytes.Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI)A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications.Microsome biocolloids for rapid drug metabolism and inhibition assessment by LC-MSCytochrome P450s and other enzymes in drug metabolism and toxicity.Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions.Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity.Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations.Assessment of drug-induced liver injury in clinical practice.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.PP2A ligand ITH12246 protects against memory impairment and focal cerebral ischemia in mice.Changes in IL-2 and IL-10 during Chronic Administration of Isoniazid, Nevirapine, and Paracetamol in Rats.Drug-induced liver injury: insights from genetic studies.Pharmacogenetics of drug-induced liver injury.Mechanisms of drug toxicity and relevance to pharmaceutical development.NMR spectroscopy as a tool to close the gap on metabolite characterization under MIST.Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.Early human ADME using microdoses and microtracers: bioanalytical considerations.Managing the challenge of chemically reactive metabolites in drug development.Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development.
P2860
Q27902347-ADDE1E6A-97FD-49FF-B252-418120320F3CQ28068710-0CC9097B-BEE4-4819-AE37-34F32F8CD28AQ28820944-9A57A64C-18B8-4334-B0BB-DD5A37308258Q29247916-23E4715B-F63E-4FB7-BF98-6863642B5948Q30011018-7B2D9963-E428-47C7-A07D-AC92F21FDBC4Q30868425-73E09E4A-E065-4BE9-9DA8-C5E6D93C7910Q33697607-A76F2B3D-CF4A-4734-B09E-C857BA0DCE8EQ33752322-2CF2DF91-5F6A-404E-A404-6823B993D04CQ33802204-9F2D649A-6743-4F8A-ADF7-4E3592379B80Q34169362-959847A8-5F78-4647-AA07-9B64733EC6A8Q34200596-F0DF506E-B373-437A-AF32-DD4956565040Q34281872-B751F25D-0FEF-4350-A674-2034AF84321FQ34378297-B2311506-D7EB-46B8-AED3-FB0642260374Q34782133-4C7FB67D-067F-48F2-B130-90F5FD5DA7B8Q34979115-67802CB1-6F54-4C07-A496-CB6A4D1B7E78Q35000102-4D59D382-1CC8-41AD-BAA3-9500D90D94CDQ35025213-5894BD1D-E00B-4932-8038-0C0EC1B95650Q35805197-E62BE613-0D96-4C23-AC91-6C0DA6E82DABQ35895187-DEDA2317-0F8C-427A-8E27-AC12E63D4BF1Q35981110-7DE3FE5A-1A02-417F-B716-DB1CEA6A2AC9Q36052505-B1ED8CB1-5910-473C-8365-D6F399E48DADQ36231948-9019D2F3-FEB6-4CF6-B158-2314E917F098Q36323058-B0AD94E7-FF67-4AD3-9ECA-2D5B2CFF2550Q36439150-C26F6031-078D-461E-9154-8BBF7DC8B4FFQ36662857-E0BEBA81-BCEB-45F7-8DA5-79BECBF96F1FQ36673575-6A1DA72D-1684-44A2-BEE1-38B585D26B8EQ36799781-5F60151E-E49F-4C51-96F7-1667824196CDQ36985079-DF0A12D8-189C-4DD7-9700-26705B36A7C5Q37114105-B420EBFA-E57F-46CA-930E-ADB184593ADCQ37121662-353BA8A6-875F-4AA8-BB25-E5CC7BE889C9Q37186184-08AB51A9-720C-4C66-9CCE-1457F00F2BCCQ37470803-671BB58C-3D15-4232-91D8-11A05DE2D2E8Q37598897-4FC24E3B-36C9-42B1-9948-A3F4F2291E9AQ37770487-A1B1922A-5274-4B24-A6B9-332E97AA8A86Q37803316-25022403-63D6-4552-B918-F59301E0E848Q37810228-9BC5DE4A-9C94-4999-955C-114E20352AB0Q37810232-382A6BA9-57AB-45D4-A10B-67E774AF75EDQ37810234-D91678A6-5B33-4241-9F8D-00F5156077BDQ37860142-9C6C2627-14B2-42D0-BEE4-3D4242F279E4Q37975546-ADF46CE7-1DE3-4FE4-825E-1423447169E5
P2860
Role of metabolism in drug-induced idiosyncratic hepatotoxicity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Role of metabolism in drug-induced idiosyncratic hepatotoxicity.
@ast
Role of metabolism in drug-induced idiosyncratic hepatotoxicity.
@en
type
label
Role of metabolism in drug-induced idiosyncratic hepatotoxicity.
@ast
Role of metabolism in drug-induced idiosyncratic hepatotoxicity.
@en
prefLabel
Role of metabolism in drug-induced idiosyncratic hepatotoxicity.
@ast
Role of metabolism in drug-induced idiosyncratic hepatotoxicity.
@en
P2093
P2860
P1476
Role of metabolism in drug-induced idiosyncratic hepatotoxicity.
@en
P2093
David C Thompson
Jennie L Walgren
Michael D Mitchell
P2860
P304
P356
10.1080/10408440590935620
P407
P577
2005-04-01T00:00:00Z